Genome & Company Report issue

Foundation Phase 2
Founded: Seoul Korea, Republic of (2015)

Organization Overview

First Clinical Trial
2020
NCT04601402
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Genome & Company

Active Ingredients

Drugs in Phase 2 Trials (2)

avelumab (bavencio) (2 trials)

gen-001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2